Register to receive a free U.S. Market Report Suite for Immunology Drugs report synopsis and brochure
Novartis’ Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data
Novartis announced first of its kind Phase III data showing Cosentyx® (secukinumab) delivered high and long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis at 5 years. This data were presented for the first time at the 26th European Academy of Dermatology and Venereology (EADV) Congress in Geneva, Switzerland.
By specifically targeting interleukin-17A (IL-17A), Cosentyx addresses the key cytokine involved in the development of psoriasis. IL-17A plays a significant role in the pathogenesis of plaque psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS). Inhibiting IL-17A is important as up to 30% of patients with psoriasis may have PsA.
“These final data are meaningful for dermatologists as they show that the high efficacy and safety of secukinumab was sustained over the 5-year treatment period.”, said Dr. Robert Bissonnette, Innovaderm Research, Montreal, Canada.
“The 5-year data reinforce Cosentyx as an important treatment option for those people living with psoriasis who aspire for skin clearance that can last,” said Vas Narasimhan, Global Head, Drug Development and Chief Medical Officer, Novartis. “Cosentyx is the first and only IL-17A inhibitor approved for psoriasis, psoriatic arthritis and ankylosing spondylitis and has been prescribed to more than 100,000 patients since launch.”
New CIMZIA® (certolizumab pegol) Findings Presented at European Academy of Dermatology and Venereology (EADV) Congress
UCB and Dermira, Inc. announced new 48-week data from three Phase 3 trials evaluating the efficacy and safety of CIMZIA® (certolizumab pegol) in adult patients with moderate-to-severe chronic plaque psoriasis. This data were presented for the first time at the 26th European Academy of Dermatology and Venereology (EADV) Congress in Geneva, Switzerland.
New 48-week safety and efficacy data from the CIMPASI-1, CIMPASI-2 and CIMPACT trials were presented, as well as patient-reported outcomes including quality of life as defined by the Dermatology Quality of Life (DLQI) and work productivity and activity impairment (WPAI) measures. CIMPASI-1 and CIMPASI-2 are randomized, blinded, parallel group, placebo-controlled, multi-center trials that have previously reported statistically and clinically significant improvements at week 16 in adult patients with moderate-to-severe chronic plaque psoriasis treated with CIMZIA compared to placebo. CIMPACT is a randomized, blinded, parallel group, placebo- and active-controlled, multi-center trial that demonstrated clinically significant improvements in skin severity at 12 weeks in patients receiving CIMZIA versus placebo. Data from all three studies demonstrated that the clinical benefit was maintained through 48 weeks in patients who responded at week 16.
Additionally, improvements in DLQI and WPAI patient-reported outcomes were demonstrated in all three trials at week 16 and maintained through week 48 in patients who responded at week 16. DLQI is a widely used and recognized quality of life measurement instrument used across several dermatological diseases. 7 The WPAI looks at the effect of dermatological conditions on factors affecting work productivity and activity impairment, which include absenteeism and work productivity loss, among others.
For Further Information
The Immunology Drugs Market Report Suite covers reports on the following markets: Rheumatoid Arthritis Treatment, Crohn’s Disease Treatment, Psoriasis Treatment, Ankylosing Spondylitis Treatment and Ulcerative Colitis Treatment.
The iData report series on immunology drugs covers the U.S., Canada, Brazil, Russia, India, China, Japan, U.K. Germany, Spain, Italy and France. Reports provide a comprehensive analysis including units sold, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about immunology drug market data, register online or email us at firstname.lastname@example.org for a U.S. Market Report Suite for Immunology Drugs brochure and synopsis.